Levari Exp.20: 2D - Partial Feedback

August 10, 2024 updated by: Jeremy M Wolfe, PhD, Brigham and Women's Hospital

Project 2: Levari Exp.20: 2D - Partial Feedback NOTE: Note, This is One of Many Studies Under Project 2 in the Original Grant

Suppose that observers are trying to classify a spot on the skin as normal or abnormal and suppose that the two attributes that are important are the color and shape of the spot. The investigators have found that perceptual decisions of this short are shaped by the prevalence of the target abnormality and by the feedback that observers (Os) receive. If abnormal spots are rare (low prevalence), Os will tend to become more conservative about calling spots abnormal. In this experiment, Os see items defined by color and shape. They are looking for one combination (bumpy green). Bumpy green targets can be common (50% prevalence) or rare (10%). Os in one group will get feedback about their responses based on color. The other group will receive feedback based on shape. The investigators will look for effects of prevalence and of the type of feedback. The goal is to better understand perceptual decisions in settings like clinical evaluation of skin lesions.

Study Overview

Detailed Description

Suppose that observers are trying to classify a spot on the skin as normal or abnormal and suppose that the two attributes that are important are the color and shape of the spot. The investigators have found that perceptual decisions of this short are shaped by the prevalence of the target abnormality and by the feedback that observers (Os) receive. If abnormal spots are rare (low prevalence), Os will tend to become more conservative about calling spots abnormal.

In this experiment, Os see items defined by color and shape. Items vary in dominant color from purple to green. Items vary in shape from relatively smooth irregular blobs (nicknamed "Bouba") to relatively bumpy blobs (nicknamed "Kiki"). Os are asked to find "Green Kikis". Since color and shape vary continuously, the border between Green Kiki and not Green Kiki will not be clear to the Os. Os will be asked to label each item as Green Kiki or not. Saying "maybe" is not an option.

The between-subject variable is the type of feedback Os receive. One set of Os will get feedback about color. That is, if the observer says "yes, this is a green kiki", they will be told only "Yes, this was a green item" or "no this was not green". The other group will get shape feedback: e.g. "Yes, this was a Kiki.".

The within-subjects variable is the target prevalence. The investigators can divide the stimuli into four quadrants: Green Kiki targets, and Green Bouba, Purple Bouba, and Purple Kiki distractors. In the high prevalence trials, 50% of the stimuli will be drawn from target quadrant (green kiki) and 17% from each of the remaining three quadrants. In the low prevalence trials, 10% of the stimuli will be drawn from the target quadrant while 30% will be drawn from each of the other three quadrants. The whole space of stimuli has 10 shape values and 10 color values for a total of 100 possible types of stimulus.

The key dependent is the proportion of target-present responses for each type of stimulus.

To analyze the data, the investigators will create a heatmap showing the percentage of times Os judge each of the 100 categories (10 colors X 10 shapes) as the target, separately for the high prevalence and low prevalence block. The investigators will calculate the response difference between the two blocks within subjects and will calculate the difference between shape and color feedback between observers.

Observers with an average accuracy below 70% will be excluded. Prior experiments have a conservative effect size of ~0.8 for differences between high and low prevalence. Some effects in experiments proposed here may have more subtle effects so power will be calculated based on an effect size of 0.6. To detect such a difference between, for instance, the 50% points on two functions like those in the data figures above, requires 26 observers to achieve alpha of 0.05 and power of 0.9. The investigators will aim for 26 observers in each condition.

Study Type

Interventional

Enrollment (Actual)

55

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Visual Attention Lab / Brigham and Women's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

normal color vision- 20/25 or better acuity

Exclusion Criteria:

no history of visual or oculomotor disease-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Color Feedback
Observers are told if the color but not if the shape was correctly identified
Feedback is given about the correctness of the response on the color dimension
Experimental: Shape Feedback
Observers are told if the shape but not if the color was correctly identified
Feedback is given about the correctness of the response on the shape dimension

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of stimuli identified as target items
Time Frame: Through study completion, an average one 1 year
Participants are presented with visual stimuli from a 10 by 10 set of 100 possibilities. There are 10 levels of color (blue to green) and 10 levels of shape (smooth="Bouba" to bumpy = "Kiki", fully crossed with each other. Participants are asked to state whether an item is or is not a "green Kiki" target. For each of the 100 items, the primary outcome measure is the percentage of time that the specific item is called "Green Kiki" target.
Through study completion, an average one 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jeremy M Wolfe, PhD, Brigham and Women's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2021

Primary Completion (Actual)

June 1, 2021

Study Completion (Actual)

June 1, 2021

Study Registration Dates

First Submitted

March 27, 2024

First Submitted That Met QC Criteria

April 2, 2024

First Posted (Actual)

April 10, 2024

Study Record Updates

Last Update Posted (Actual)

August 13, 2024

Last Update Submitted That Met QC Criteria

August 10, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2007p000646-F

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

de-identified data will be posted on the Open Science Framework site

IPD Sharing Time Frame

available after data collection, no end time

IPD Sharing Access Criteria

openly available

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Decision Making

Clinical Trials on Color Feedback

Subscribe